Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sangdantongluo is a Traditional Chinese Medicine (TCM) herbal formulation, typically administered in granule form, developed for the treatment of post-stroke spasticity. It is currently being investigated by the Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine (Hunan Academy of Chinese Medicine Affiliated Hospital) to elucidate its underlying neuromechanisms. Research utilizes multimodal functional Magnetic Resonance Imaging (fMRI) and Transcranial Magnetic Stimulation (TMS) to provide imaging evidence of its efficacy in modulating neural plasticity and improving motor function. As a "Tongluo" (collateral-unblocking) agent, it aims to restore flow and function in the neurological pathways affected by ischemic or hemorrhagic stroke.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sangdantongluo.